The Abnormal increase in the mass of adipose tissue during adipogenesis results in obesity. Obesity is a predominant disorder and its widespread has become a critical concern worldwide. This is due to the burden of its associated co-morbidities like cancer, cardiovascular diseases and diabetes. Over-nutrition and the sedentary lifestyle are considered as the most significant causes of abnormal adipose tissue development. Appropriate lifestyle and behavioural interventions are the corner stones of successful weight loss, but to maintain such a lifestyle is highly challenging. Accordingly, natural products from plants either as crude extracts or purified phytochemicals have shown to have anti-obesogenic properties and are generally non-toxic and cost-effective. In this review, we discuss the comparative analysis of molecular mechanisms involved in adipogenesis and the recently reported anti-obesogenic effects of various plant products. We will provide a common platform for understanding obesity and adipogenesis, and a possible mechanism of action for anti-obesogenic plant products through AMP-activated protein kinase (AMPK), which will support the scientific development of traditional herbal medicine.
profound changes in the extracellular matrix (ECM), morphology of the cell and cytoskeletol components [22] . ECM provides strength, structural support, sites for the attachment of cell receptors, and acts as a source of cell signaling factors. In adipose tissue, ECM interconnects the adipocytes which results in the formation of fat lobules in vivo and cluster of fat cells in vitro [21] . ECM may also modulate the differentiation of adipocytes. For instance, proteolytic degradation of the extracellular matrix of pre-adipocytes by cascade of plasminogen is essential for changes in the expression of adipocyte genes and deposition of fats [18, 23] . Recently, it has been revealed that events and changes (molecular and morphological) which are associated with the above-mentioned changes may modulate adipogensis directly, because they alter the expression of positive transcriptional regulators of adipogenesis such as PPARγ and C/EBPα [23] . The components of ECM consist of classes of adhesion proteins such as laminin and fibronectin, and various types of collagen. Type I, III and VI collagens are considered the most essential isotypes here, due to their usual association with the fibrotic depots of an organ [24] . Inhibition of the synthesis of collagen prohibits the differentiation of pre-adipocytes, demonstrating that active collagen synthesis is also necessary for the differentiation of pre-adipocytes [21] .
White, Beige and Brown Adipose Tissues
Generally, there are two main types of adipose tissues in mammals; WAT and brown adipose tissue (BAT). The adipocytes of these two tissues possess different functions and morphology. WAT cells each contain a single lipid droplet of triglycerides formed from esterification of fatty acids and glycerol-3-phosphate. BAT contains high numbers of mitochondria and multilocular lipid droplets.
The main constituent of adipose tissue is WAT, which is used as an energy substrate when needed.
WAT adipocytes have a greater average diamter than those of BAT. WAT stores triglycerides while BAT disperses energy by producing heat, thus there is an antagonistic relationship between the two [2, 25] . BAT is known to be protective against hypothermia due to its capacity to break down lipids to generate heat (thermogenesis). Uncoupling protein1 (UCP1) is the key player for thermogenic property of BAT [26] . UCP1, responsible for the uncoupling of electron transport for ATP production, is characteristically expressed by the mitochondria in BAT, thus allowing thermogenesis [27] .
presence and functional relevance of BAT [34] and brite adipose tissue in adults as well [35] . Although both brown and white adipocytes originate from MSCs, it is believed that the precursor cells giving rise to brown and white adipocytes are different ( Figure 1 ). MSCs are pledged either to adipogenic (Myf-5 negative) cells and give rise to white adipocytes or myogenic (Myf-5 positive) cells, giving rise to brown adipocytes [36, 37] . The Myf-negative precursor cells give rise to white pre-adipocytes through the expression of bone morphogenetic protein-2 and 4 (BMP 2 and 4). Similarly, the Myfpositive precursor cells give rise to brown pre-adipocytes through bone morphogenetic protein-7 (BMP 7) expression and trancriptional co-regulator PR-domain containing 16 (PRDM16) [36, 38] . The recent rediscovery of effective BAT in adult humans has invigorated interest in it as a viable and novel target for phytochemicals. Upregulating the proteins and transcriptional factors specifically expressed in brown or beige adipocytesis is a highly promising approach in the elimination of obesity. Activation of the thermogenic system in humans, either in WAT or BAT, should correlate well with an increase of energy expenditure. Interest in the prevention of obesity by regulation of non-shivering thermogenesis in BAT and brite adipose tissue through phytochemicals has been increasing rapidly due to their potential for side-effect-minimal medication. Various phytochemicals have been reported (Table 1) to activate browning of WAT, indicating their thermogenic effects. For example, genistein upregulates peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgc1α), Ucp1 and Sirtuin 1 (Sirt1) expressions [39] , hence promotes brown adipogenesis. Similarly, Formononetin [40] and Myricetin [41] have also been reported to cause browning of WAT by upregulating the genes and transcriptional factors specifically expressed in BAT. [48] iWAT; Inguinal white adipose tissue,
Transcriptional Regulators of Adipogenesis
Adipogenesis requires upregulation of several transcription factors including the C/EBP family members and PPARγ [18] . Expression of the two members of C/EBP family (C/EBPβ and C/EBPδ) occurs at early stages of adipocyte differentiation and then together, they induce the expression of C/EBPα and PPARγ which are the central positive modulators of adipogenesis [49, 50] . PPARγ is the master regulator involved in the differentiation of adipocytes and metabolism [51] . PPARγ and C/EBPα exert positive feedback on each other and regulate the process of adipogenesis positively ( Figure 2 ). Several studies [52, 53] have indicated that PPARγ is the key regulator involved in the development and differentiation of adipocytes, and therefore known to be obligate for the differentiation of adipocytes. Expression and normal function of PPARγ is necessary for the progression of adipogenesis: cells deficient in PPARγ cannot differentiate into mature adipocytes even if other powerful pro-adipogenic factors are ectopically expressed [50] . Previous in vitro studies have shown that most of the activators and repressors of adipogenesis alter the activity and expression of PPARγ [54] . Transcriptional factors such as C/EBP β, C/EBP δ, kruppel like factor 5 (KLF5) and early β-cell factor 1 (EBF1) are known to directly induce the expression of PPARγ mRNA in adipogenesis [50] . Early β-cell factor 1 and 2 (EBF1 and EBF2) are induced during 3T3-L1 white pre-adipocytes differentiation but their pattern of expression is different [55] . EBF2 has been reported to regulate brown adipocytes genes expression; Ucp1 and Prdm16 and express at higher levels in BAT as compared to WAT [56] . In addition, there are other substantial transcriptional factors that act also as regulators of adipogenesis. Kruppel like factors (KLFs) are either activators or suppressors of adipogenesis. KLF4, KLF5, KLF6, KLF9, KLF13 and KLF 15 are known to enhance adipogenesis while KLF 2, 3, 7 and 16 inhibit adipogenesis [17, [57] [58] [59] . KLF2 directly inhibits the PPARγ promoter.
Adenovirus-mediated ectopic expression of KLF2 has been reported to inhibit the expression of C/EBPα ,PPARγ and SREBP-1c but did not have any effect on C/EBPδ and C/EBPβ expression [60] .
KLF3 inhibits 3T3-L1 pre-adipocytes differentiation by repressing C/EBPα promoter [59] . Similarly, overexpression of KLF7 is also reported to inhibit 3T3-L1 pre-adipocytes differentiation [61] . Over expression of KLF7 significantly decreases C/EBPα, PPARγ, adipsin and adipocyte protein-2 (aP2) expression [62] . Globin transcription factors GATA2 and 3 are also reported to decrease adipogenesis by down-regulating PPARγ expression [49, 63] . Other transcriptional factors such as cyclic AMP response binding element (CREB) and sterol regulatory binding protein-1 (SREBP1), (which expedites metabolism of fatty acids by inducing expression of PPARγ) are needed in the differentiation of pre-adipocytes into mature adipocytes [49] . In pre-adipocytes CREB is required for the induction of differentiation of adipocytes and absence of CREB inhibits pre-adipocytes differentiation into mature adipocytes [64] . 
Role of Signaling Pathways in Adipogenesis
MSCs are commited to either osteogenic or adipogenic lineages. This involves discrete signaling pathways including Bone morphogenetic protein (BMP), Wnt (canonical and non-canonical), and
Hedgehog signaling pathways. These pathways have very strong influences on the central regulators of both osteogenesis (Runx2) and adipogenesis (PPARγ), two factors which are responsible for the differentiation of MSCs into either osteocytes or adipocytes and work antagonistically with overexpression of one factor repressing the other [65, 66] .
Bone Morphogenetic Proteins and Transforming Growth Factors-β Pathway
Bone morphogenetic proteins (BMPs) belong to the superfamily of transforming growth factorsβ (TGF-β) and have been identified as regulators of osteogenesis and adipogenesis [65, 67] . BMPs are involved in the differentiation of disparate cell types including adipocytes. Initially, BMPs were thought to have a critical role only in the formation of bone, but their role in all other organs has been discovered recently [68] . BMPs are known for their regulatory roles in various cellular process including proliferation, apoptosis, differentiation, and determination of cell fate in adulthood and during embryogenesis [67] [68] [69] . BMPs play different roles in the differentiation of adipocytes depending on the stage of cells and BMP type and dosage [70] . BMP-2 in particular, inhibits adipogenesis and promotes osteogenic differentiation in bone marrow stromal cells [71] . BMP-7 has been shown to activate brown adipocytes differentiation [72] . 3T3-F44 2A pre-adipocytes treated with BMP-2 showed a decrease in insulin-induced lipid accumulation [73] , but BMP-7 increased the differentiation of 3T3-L1 pre-adipocytes, demonstrating the contradictory roles of BMPs in adipogenesis [74, 75] . Similarly, BMP-4 regulates the commitment of precursor cells into white Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 23 July 2019 doi:10.20944/preprints201907.0040.v2
adipogenic lineage [76] . BMP-4 and BMP-7 can also activate development of beige adipocytes in human precursor cells [77] . Overexpression of BMP-4 in transgenic mice showed a reduction in the size and mass of WAT, and induced browning of WAT (known as britening) [78] . Induced expression of BMP-4 upregulated the expression of key regulators of brown adipose tissue, peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α) and its target gene, UCP1 [79, 80] .
The 33 members of the TGF-β superfamily also have wide roles in different types of cells, including adipocytes. Among all the TGF-β superfamily members, TGF-β1 has a major role in adipogenesis. It inhibits 3T3-L1 pre-adipocytes differentiation into mature adipocytes [81] by interacting and repressing essential adipogenic factors PPARγ, C/EBPα and C/EBPβ [67] . These pathways are therefore of great interest for the discovery of new and non-toxic chemotherapies in preventing obesity through inhibition of WAT development, and promotion of BAT by targeting the key factors of these pathways.
Wnt Signaling Pathway
Wnts (Wingless-type MMTV integration site family members) are secreted glycoproteins that work both in an autocrine and paracrine manner [67] . Wnt signaling pathways are a group of conserved signal transduction pathways and consist of proteins which convey signals through cell surface receptors into the cell. These pathways are involved in processes including cell differentiation and proliferation in adult tissue regeneration, and in embryonic development [67] . These signal transduction pathways can be divided into canonical (β-catenin dependent) and non-canonical (βcatenin independent) pathway. Wnt proteins control the proliferation of cell, cell fate, behaviour and survival by exerting signals through these canonical and non-canonical pathways. MSCs are differentiated into osteocytes and myocytes instead of adipocytes upon Wnt/β-catenin signaling pathway activation. Conversely, interruption of Wnt/β-catenin signaling promotes adipogenesis [82] .
One important element of the Wnt/β-catenin pathway, Wnt10b, had been reported to be responsible for the anti-adipogenic function of canonical pathway. Wnt10b is highly expressed in pre-adipocytes but its expression declines promptly after induction of differentiation [83] . Its overexpression stabilizes cytoplasmic β-catenin and block adipogenesis in 3T3-L1 pre-adipocytes [84, 85] . Moreover, the Wnt/β-catenin signaling pathway also inhibits brown adipogenesis by disrupting the PPARγ and C/EBPα induction. Wnt10a and Wnt10b, members of the canonical pathway, are possible endogenous inhibitors of BAT. Both Wnt10b and Wnt10a are expressed in pre-adipocytes of BAT but not in differentiated brown adipocytes and their expression reduces with the progression of brown adipogenesis [86] . In addition, Wnt signaling also blocks the thermogenic program of BAT by suppressing the thermogenic protein, UCP1 of BAT through repression of PGC1-α [86] . In vivo expression of Wnt10b from fatty acid binding protein 4 (FABP 4) promoter had been shown to reduce total body fat by 50% and provide resistance to WAT accumulation in high fat diets, as well as blocking the development of BAT [87] . These findings had led to the conclusion that the activation of investigate further other bioactive compounds and their mechanism of action in inhibiting adipogenesis through Wnt/β-catenin signaling pathway.
Besides the canonical pathway, members of Wnt family also activate the non-canonical β-catenin independent pathway. Activation of non-canonical pathway through Wnt5a is reported to antagonize the canonical pathway, promoting the differentiation of pre-adipocytes [90]. GSK-3: Glycogen synthase kinase 3.
Hedgehog Signaling Pathway
The Hedgehog (Hh) signaling pathway is involved in the development of both vertebrates and invertebrates [91] . It is known to be one of the important modulators of the stem cell differentiation process and its role in the differentiation of MSCs had been demonstrated in several studies [92, 93] .
This signaling pathway is downregulated during the differentiation of human adipocytes, and upon activation it reduces the expression of key adipogenic transcription factor C/EBPα and hinders accumulation of lipids and adipogenesis [67, 93] . Hh signaling pathway activation in C3H10T1/2 mouse cells was reported to inhibit PPARγ and C/EBPα expression, blocked the differentiation of pre-adipocytes into mature adipocytes and increased the commitment of C3H10T1/2 mouse cell lines towards osteogenic lineage [94] . 
AMPK; Central Target of Many Natural and Synthetic Compounds
AMPK is a serine/threonine kinase. The heterotrimeric protein consists of 3 subunits: catalytic subunit α which contains further two subunits α1, α2 and regulatory subunits β and γ consisting of two subunits (β1, β2) and three subunits (γ1, γ2, γ3) respectively [95, 96] . Being expressed in different kind of tissues (liver, adipose, skeletal, kidney and hypothalamus), [97] AMPK plays a significant role in controlling and regulating cell cycle and cellular energy homeostasis; it is therefore the most widely studied protein in the investigation and discovery of natural as well as pharmacological compounds against weight loss.
Metabolic Functions of AMPK and Role in Adipogenesis
Once activated, AMPK directly or indirectly promotes the phosphorylation of downstream targets including transcription and translational factors, metabolic enzymes, epigenetic factors, growth and proliferation pathways. The overall effect of this regulation is to reduce the synthesis of cholesterol, fatty acids, ribosomal RNAs (rRNAs) and proteins [98] , making AMPK a potential target of high value for the development of pharmacological and natural anti-obesogenic compounds [99] .
In adipose tissue, activation of AMPK correlates with decreased level of lipid storage [16] . Regulation of lipids metabolism is the first known function of AMPK. AMPK inhibits de novo synthesis of cholesterol, triglycerides (TG), and fatty acids (FAs), and activates FA uptake and β-oxidation (FAO).
It inhibits and phosphorylates targets involved in the synthesis of fatty acids such as FAS, ACC1, and SREBP1c ( Figure 4 ). SREBP1c is involved in the transcriptional regulation of various lipogenic enzymes including FAS and ACC1. ACC1 converts acetyl-coA to malonyl co-A and hence catalyzes the rate limiting step in the synthesis of FAs [100, 101] . Moreover, AMPK inhibits synthesis of cholesterol by phosphorylating and inhibiting HMG-CoA-reductase [100] . It is also known for its inhibitory effects on the mammalian target of rapamycin (mTOR) which is the fundamental cell growth regulator and is highly conserved in all eukaryotes. AMPK remains active under poor energy and nutrient conditions while mTOR remains inactive in such conditions [102] . Thus, the inhibiting effects of AMPK on mTOR define antigrowth and antiproliferative activities under stress conditions.
AMPK may therefore play a significant role in the inhibition of adipogenesis by inhibiting the mTOR signaling pathway. In the case of obesity, AMPK remains inactive due to the availability of excess nutrients and energy sources, therefore an external stimulus is needed to activate AMPK. Much effort has been spent attempting to delineate the exogenous activators of AMPK, and the debate is still ongoing. The net effect of AMPK activation is an increase in body's cellular energy level [97] .
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the important functions of AMPK. Therefore, the protein is a key therapeutic target for the treatment of major metabolic disorders including obesity and type-2 diabetes [103] . As adipogenesis is an energy consuming process, AMPK regulates the inhibition of expression of FAS, adipocyte specific pre-adipocytes, highlighting the potential role of AMPK in the inhibition of adipogenesis [111] In addition, AMPK has also been shown to be pertinent in the britening of WAT thereby increasing the energy expenditure through thermogenesis [112, 113] . It has also been reported that the activity of AMPK increases during the differentiation of brown adipocytes and that targeting AMPK by short interfering RNAs (siRNAs), inhibits the differentiation of pre-adipocytes into mature brown adipocytes [16, 114] . These studies clearly indicate AMPK as a potential therapeutic target in the prevention and treatment of many metabolic diseases including obesity. thus inhibits adipogenesis and lipogenesis in adipocytes. CPT1: carnitine palmitoyltransferase 1.
AMPK Activation by Upstream Kinases
AMPK is broadly known as a fuel-sensing enzyme -it is involved in sensitivity to, and the homeostasis of lipids, glucose and insulin [115] . Under different physiological conditions, the subunits of AMPK behave and are regulated differentially. Activation of AMPK can be achieved by either through upstream kinases or allosterically through AMP [97] . It is activated when there is increase in the consumption of adenosine triphosphate (ATP) which leads to an increase in the ratio of adenosine monophosphate (AMP) to ATP [116] . The best studied mechanisms of the activation of [123] . Therefore, further study about activation of AMPK in adipose tissue by anti-obesogenic products through upstream kinases is required to understand their mechanism of action and develop new anti-obesogenic products specifically targeting these kinases to treat adiposity.
Exogenous Activators of AMPK
In recent years, much effort had been made to delineate the pathways of AMPK, and to identify 
Direct Exogenous Activators
Activators that bind directly to AMPK and activate it without significant changes in ATP:AMP ratio are known as direct activators. Direct activators induce conformational changes in the AMPK complex, more specifically by interacting with one of the AMPK subunits. AICAR was the first identified direct activator of AMPK in vitro and in vivo [124] . To evaluate the downstream effects of activated AMPK in animals, AICAR had been used widely [124] . Structurally AICAR is similar to adenosine, and it is similarly phosphorylated upon entering the cell (via adenosine transporters) to AICAR monophosphate (ZMP) by adenosine kinase. ZMP is an analog of adenosine monophosphate (AMP) and similarly activates AMPK allosterically by binding to its γ subunit. This causes an increase in Thr172 phosphorylation of α subunit of AMPK [96] , and also inhibits the dephosphorylation of AMPK [124] . Treatment with AICAR had been shown to increase glucose tolerance, reduce TGs and free fatty acids (FFAs) level of plasma. AMPK activation by AICAR has been reported to suppress the activation of adipogenic transcription factors C/EBPα and PPARγ, and the enzymes acetyl-CoA carboxylase and FAS [125] . AICAR has also been known to cause arrest of cell cycle at the G1 phase by inducing activation of p53 followed by activation of the cell cycle inhibitor protein p21 [126] , stopping the growth and proliferation of cell cycle under stress conditions. Although AICAR has promising effects as mentioned above, since it mimics the effects of AMP, it has also other AMPKindependent effects [124] . For instance, it regulates other AMP-regulated enzymes such as fructose-1,6-bisphosphatase (FBPase) and stimulates muscle glycogen phosphorylase [124, 127] . In addition, due to short half-life and poor bioavailability, it is unlikely to be used in the treatment of metabolic syndrome and Type-2 diabetes [128] and these are considered to be the main obstacles in the development of AICAR as a promising drug [124] .
Other direct activators (i.e. independent of upstream kinases) of AMPK include A-769662 compound (Thienopyridone Family), Compound 991 (Benzimidazole family), and salicylate. A-769662 belongs to thienopyridone family and is a small organic compound which activates AMPK allosterically by phosphorylating AMPK at Ser108 in the AMPKβ subunit, especially β1 [96] and inhibits dephosphorylation of Thr172 in AMPKα subunit [129, 130] . Activation of AMPK both by A-769662 and AMP have been extensively studied in vivo and in vitro. AMP and A-769662 compound had been reported to bind to different sites on AMPK and have different mechanism of actions [96, 130] . Another direct activator of AMPK is referred to as Compound 991 and belongs to benzimidazole family. It is reported to bind the β unit of AMPK and is more effective (5-10 fold) than A-769662 in the allosterical activation and inhibiton of dephosphorylation of AMPK [96, 131] . Similar to A-769662, compound 991 failed to activate AMPK complexes which contained mutations in the Ser108 of the β subunit of AMPK. This suggest that both A-769662 and compound 991 show similar mechanism for the activation of AMPK [131] . Salicylate is among the oldest drugs used by humans.
It is a phytochemical, produced naturally and obtained from willow bark [128] but for medicinal purposes, it is now used in acetylated form (Aspirin) [129] . Aspirin is easier to take orally than salicylate, and upon entering the blood stream, it is rapidly broken down to salicylate [96] . Salicylate binds to the β1 subunit (the same unit where A-769662 compound binds) of AMPK and thus activates AMPK allosterically, inhibiting the dephosphorylation of Thr172 in the α subunit [132] . AMPK but unlike AICAR, it does not have any effect on the enzymes which use AMP as a substrate, namely 6-phosphofructo-1 kinase (PFK1), fructose-1,6-bisphosphatase-1 (FBP1) and muscle glycogen β [133] . Compound-2 is known to be two folds more potent than AMP and 20 folds more than A-769662 [96].
Indirect Exogenous Activators
Studies have shown that modulators which can cause calcium or AMP accumulation in the body can activate AMPK [96] . These modulators are known as indirect activators of AMPK and maybe physiological, pharmacological and natural activators. These modulators do not encompass direct interaction with AMPK, they can activate AMPK either by increasing AMP:ATP or calcium accumulation in the bodies [96, 128] . Pharmacological and phytochemical activators of AMPK such as metformin, troglitazone, quercetin, genistein, epigallocatechin gallate, resveratrol, berberine, curcumin and α-lipoic acid act as indirect activators of AMPK [96] , activating the kinase by expenditure of energy because when ATP is decreased, AMP is increased. Metformin is a biguanide which is found in Galega officinalis. It upregulates the activity of AMPK, increases the oxidation of fatty acids, downregulates lipogenic genes, increases the glucose uptake and decreases the production of glucose. Metformin activates AMPK indirectly, by binding and inhibiting the complex I of the mitochondrial respiratory chain, thus increases AMP:ATP ratio. It also inhibits the dephosphorylation of AMPK and increases the phosphorylation of AMPK through upstream kinase of AMPK, LKB1 [129] . Thiazolidinediones (TZDs) are insulin-sensitizing drugs and consist of rosiglitazone, pioglitazone and troglizatone [128] ; these compounds indirectly activate AMPK and promote phosphorylation of ACC in various types of tissues including adipose, skeletal muscles and liver [128, 134] . They enhance the accumulation of AMP by inhibiting the complex I of the mitochondrial respiratory chain and hence activate AMPK indirectly [135] . Moreover, they enhance the expression of PPARγ which in turn increases the release and expression of adiponectin from adipocytes [134] , activates AMPK in skeletal muscle and liver, increases the oxidation of fatty acids and uptake of glucose, and decreases the production of hepatic glucose [96] .
Indirect activation of AMPK by phytochemicals had also been reported in numerous studies.
Quercetin is one of the most abundant flavonoids found in many plants, food and grains, and is known to activate AMPK indirectly [106] . Exposure of 3T3-L1 cells to quercetin resulted in a decrease expression of positive regulators of adipogenesis and attenuation of adipogenesis. This was due to the phosphorylation of AMPK and its downstream substrate ACC [106] . Another indirect activator of AMPK that can be found in grapes is resveratrol. Resveratrol activates AMPK indirectly by increasing AMP:ATP ratio through inhibition of mitochondrial ATP production [107, 124, 136] .
Treatment with resveratrol has been shown to stimulate mitochondrial biogenesis, glucose uptake and reduce accumulation of lipids in different types of cells [128, [137] [138] [139] . In addition, Curcumin rodents activate AMPK and accordingly is the one of the most compelling enzymes through which exercise conveys conclusive effects [128, 141] .
While intracellular energy level is a crucial determinant in the activity of AMPK, it had been reported that reactive oxygen species (ROS) also induce the activation of AMPK without any decrease in ATP level [96, 142, 143] . From the pharmacological point of view, there is still much effort needed to combat obesity through direct or indirect activation of AMPK via exogenous activators with no (or minimal) side effects. Studies on direct or indirect activators of AMPK have been performed in vitro and in vivo, but more efforts are needed to evaluate their anti-obesogenic effects prior to clinical testing in humans. Moreover, these compounds must be evaluated for their toxicity and side effects before forwarding them into market. 
Anti-Obesogenic Effects of Plant Products and Their Mechanism of Action
It is evident from the literature that down-or upregulation of hundreds of transcriptional factors, hormones, and enzymes may induce obesity. Accordingly, there is no single mechanism of action of the various phytochemicals/plant products tested in the management of obesity. Different kinds of plant products have different types of mechanisms (Table 2) . Their mechanism of action may include: 1. Inhibition of Pancreatic Lipase (PL) Activity. PL is a crucial enzyme which hydrolyzes triglycerides into monoglycerides and fatty acids. It hydrolyses 50-70 % of the total dietry fat [144] and the inhibition of this enzyme is among approaches used to combat obesity. The mechanism involves inhibition of absorption of triglycerides in the bodies. PL inhibition is being widely studied to evaluate the potential of natural products to inhibit dietary fat absorption [145] [146] [147] . 2. Increase in Energy Expenditure. As mentioned above, brown adipose tissues transform energy from stored fat into heat (thermogenesis). UCP1 is the central activator of thermogenic effect and induction of its expression by natural anti-obesogenic plant products is one route to reduce obesity [7, 148] . 
Summary and Outlook
Obesity is a common disorder caused by the interaction of environmental, genetic and nutritional factors, and its pervasiveness is accelerating worldwide. Changes in lifestyle, extensive consumption of calorific foods, and increasingly sedentary lifestyles are the predominant causative factors for this rise in obesity. Returning to healthy lifestyles, for example daily exercise and consumption of food rich in minerals and fibres is the surest route to successful weight loss, but for many it is extremely challenging to maintain. For decades, synthetic chemicals had been explored to fill this need. Despite generating positive results, they have also caused adverse effects that muted their benefits. Traditionally used medicinal plants which contain a wide range of natural chemicals have been used for the treatment of many infectious as well as chronic disorders including obesity.
These natural products from plants (phytochemicals) may play a supportive role in combating obesity by helping obese people to lose weight. A synergestic activity could be conferred by the combination of multiple natural products to increase their anti-obesogenic activities and mode of action on multiple targets, which may prove to be advantageous over other chemical treatments.
Anti-obesogenic studies either based on in vitro studies or mouse models do not guarantee the same results in humans, and so clinical trials must be performed to evaluate the effectiveness of bioactive 
